The current price of WXIBF is $6.07 — it has increased by 9.67% since the previous close. Data as of Nov 4, 2026.
WXIBF is up 6.68% over the past week, down 10.34% over the past month and up 34.89% over the past year. The price is above its 200-day moving average of $5.07.
WuXi Biologics (Cayman) Inc. has a market capitalization of $24.99B. The company belongs to the Healthcare sector. Compare it with other companies in the stock screener.
In its most recent quarterly report, WuXi Biologics (Cayman) Inc. posted earnings of $0.08536 per share against an estimate of $0.06623, beating expectations by 28.88%. Upcoming reports are listed in the earnings calendar.
WuXi Biologics (Cayman) Inc. reported revenue of $1.73B in its most recent quarter, which has increased by 24.99% compared with the same quarter a year earlier. Analysts had expected $1.69B.
WuXi Biologics (Cayman) Inc. has not paid any dividends over the past year.
Companies most comparable to WuXi Biologics (Cayman) Inc. include Samsung Biologics Co.,Ltd., WuXi AppTec Co., Ltd., WuXi XDC Cayman Inc, Genscript Biotech Corporation and Lonza Group AG.
In the latest trading session WXIBF moved between $6.07 and $6.45, a range of 6.26% of its current price.
Investing in stocks requires thorough research: study the company's financials, related news and technical analysis before making a decision. Technical analysis of WuXi Biologics (Cayman) Inc. shows a buy rating today. Technical ratings are indicators, not investment advice.
Over the past 52 weeks WXIBF has traded between $3.90 and $7.49. The current price is 18.96% below its 52-week high.
Figures as of Nov 4, 2026. This information is provided for general purposes only and is not investment advice.